AIM: To identify electroencephalographic (EEG) biomarkers for the analgesic effect of pregabalin in patients with chronic visceral pain. METHODS: This was a double-blind, placebo-controlled study in 31 patients suffering from visceral pain due to chronic pancreatitis. Patients received increasing doses of pregabalin (75mg-300mg twice a day) or matching placebo during 3 weeks of treatment. Pain scores were documented in a diary based on a visual analogue scale. In addition, brief pain inventory-short form (BPI) and quality of life questionnaires were collected prior to and after the study period. Multi-channel resting EEG was recorded before treatment onset and at the end of the study. Changes in EEG spectral indices were extracted, and individual changes were classified by a support vector machine (SVM) to discriminate the pregabalin and placebo responses. Changes in individual spectral indices and pain scores were correlated. RESULTS:Pregabalin increased normalized intensity in low spectral indices, most prominent in the theta band (3.5-7.5Hz), difference of -3.18, 95% CI -3.57, -2.80; P= 0.03. No changes in spectral indices were seen for placebo. The maximum difference between pregabalin and placebo treated patients was seen in the parietal region, with a classification accuracy of 85.7% (P= 0.009). Individual changes in EEG indices were correlated with changes in pain diary (P= 0.04) and BPI pain composite scores (P= 0.02). CONCLUSIONS: Changes in spectral indices caused by slowing of brain oscillations were identified as a biomarker for the central analgesic effect of pregabalin. The developed methodology may provide perspectives to assess individual responses to treatment in personalized medicine.
RCT Entities:
AIM: To identify electroencephalographic (EEG) biomarkers for the analgesic effect of pregabalin in patients with chronic visceral pain. METHODS: This was a double-blind, placebo-controlled study in 31 patients suffering from visceral pain due to chronic pancreatitis. Patients received increasing doses of pregabalin (75mg-300mg twice a day) or matching placebo during 3 weeks of treatment. Pain scores were documented in a diary based on a visual analogue scale. In addition, brief pain inventory-short form (BPI) and quality of life questionnaires were collected prior to and after the study period. Multi-channel resting EEG was recorded before treatment onset and at the end of the study. Changes in EEG spectral indices were extracted, and individual changes were classified by a support vector machine (SVM) to discriminate the pregabalin and placebo responses. Changes in individual spectral indices and pain scores were correlated. RESULTS: Pregabalin increased normalized intensity in low spectral indices, most prominent in the theta band (3.5-7.5Hz), difference of -3.18, 95% CI -3.57, -2.80; P= 0.03. No changes in spectral indices were seen for placebo. The maximum difference between pregabalin and placebo treated patients was seen in the parietal region, with a classification accuracy of 85.7% (P= 0.009). Individual changes in EEG indices were correlated with changes in pain diary (P= 0.04) and BPI pain composite scores (P= 0.02). CONCLUSIONS: Changes in spectral indices caused by slowing of brain oscillations were identified as a biomarker for the central analgesic effect of pregabalin. The developed methodology may provide perspectives to assess individual responses to treatment in personalized medicine.
Authors: Søren Schou Olesen; Stefan A W Bouwense; Oliver H G Wilder-Smith; Harry van Goor; Asbjørn Mohr Drewes Journal: Gastroenterology Date: 2011-04-14 Impact factor: 22.682
Authors: Hans-Peter Landolt; Julia V Rétey; Karin Tönz; Julie M Gottselig; Ramin Khatami; Isabelle Buckelmüller; Peter Achermann Journal: Neuropsychopharmacology Date: 2004-10 Impact factor: 7.853
Authors: Harold A Rocha; John Marks; Adam J Woods; Roland Staud; Kimberly Sibille; Andreas Keil Journal: Clin Neurophysiol Date: 2020-08-26 Impact factor: 3.708
Authors: Michelle A Anderson; Venkata Akshintala; Kathryn M Albers; Stephen T Amann; Inna Belfer; Randall Brand; Suresh Chari; Greg Cote; Brian M Davis; Luca Frulloni; Andres Gelrud; Nalini Guda; Abhinav Humar; Rodger A Liddle; Adam Slivka; Rachelle Stopczynski Gupta; Eva Szigethy; Jyothsna Talluri; Wahid Wassef; C Mel Wilcox; John Windsor; Dhiraj Yadav; David C Whitcomb Journal: Pancreatology Date: 2015-11-11 Impact factor: 3.996
Authors: Gregory P Boivin; Debra L Hickman; Michelle A Creamer-Hente; Kathleen R Pritchett-Corning; Natalie A Bratcher Journal: J Am Assoc Lab Anim Sci Date: 2017-09-01 Impact factor: 1.232